Journal
INFLUENZA AND OTHER RESPIRATORY VIRUSES
Volume 14, Issue 4, Pages 460-464Publisher
WILEY
DOI: 10.1111/irv.12725
Keywords
antiviral resistance; baloxavir marboxil; I38T; influenza viruses; pyrosequencing
Categories
Funding
- Department of Health, Australian Government
- National Institute of Allergy and Infectious Diseases
Ask authors/readers for more resources
Baloxavir marboxil is a novel endonuclease inhibitor licensed for treatment of otherwise healthy or high-risk individuals infected with influenza. Viruses with reduced baloxavir susceptibility due to amino acid substitutions at residue 38 of the PA have been detected in some individuals following treatment. Here, we describe a genotypic pyrosequencing method that can be used to rapidly screen circulating influenza A and B viruses for substitutions in the PA/I38 codon and to quantify mixed viral populations. This method is suitable for surveillance of baloxavir susceptibility and to analyse samples from hospitalised patients undergoing baloxavir treatment to aid in clinical decision making.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available